Literature DB >> 22882953

Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.

Ya-Dan Wang1, Guo-Hui Cui, Mian Li, Bhuveshwarnath Gowrea, Jia Xia, Yu Hu.   

Abstract

Imatinib mesylate is a molecular targeted agent for treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumor. Although imatinib mesylate is not regarded as an immunosuppressive agent, few studies have also shown that it may impair immune response. In this report, we present a case of transient hepatitis B virus (HBV) reactivation during imatinib mesylate treatment for CML.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22882953

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


  10 in total

Review 1.  Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

Authors:  Venessa Pattullo
Journal:  World J Hepatol       Date:  2015-05-08

Review 2.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Hepatitis B virus infection in patients with blood disorders: a concise review in pediatric study.

Authors:  N Mansouri; A Movafagh; A Sayad; S Ghafouri-Fard; H Darvish; D Zare-Abdollahi; B Emamalizadeh; F Shahvaisizadeh; H Ghaedi; M Bastami; M Kayyal; M Hashemi; Mh Heidari; A Nejatizadeh; M Zamani
Journal:  Iran J Ped Hematol Oncol       Date:  2014-12-10

Review 4.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

5.  Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase.

Authors:  Lidan Hou; Jie Zhao; Shaobing Gao; Tong Ji; Tianyu Song; Yining Li; Jingjie Wang; Chenlu Geng; Min Long; Jiang Chen; Hui Lin; Xiujun Cai; Yong Cang
Journal:  Sci Adv       Date:  2019-02-06       Impact factor: 14.136

6.  Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report.

Authors:  Welda E H Tjhoi; Kai Li; Chun-Hui Shou; Wei-Li Yang; Ji-Ren Yu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

Review 7.  Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened.

Authors:  Soheil Tavakolpour; Seyed Moayed Alavian; Shahnaz Sali
Journal:  Hepat Mon       Date:  2016-03-26       Impact factor: 0.660

8.  Hepatitis B Virus Reactivation under Treatment with Nilotinib.

Authors:  Tuncer Temel; Eren Gunduz; Esmira Sadigova; Hava Uskudar Teke; Safak Meric Ozgenel; Aysegul Harmanci Ozakyol
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09

9.  Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report.

Authors:  Gian Paolo Caviglia; Antonella Zorzi; Mario Rizzetto; Massimo Mirandola; Antonella Olivero; Giada Carolo
Journal:  Diagnostics (Basel)       Date:  2021-11-24

10.  Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Authors:  Guan-Min Lai; Sheng-Lei Yan; Cheng-Shyong Chang; Chien-Yu Tsai
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.